



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## A-437203

<b>Cat. No.:</b>	HY-U00185		
<b>CAS No.:</b>	220519-06-2		
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>27</sub> F <sub>3</sub> N <sub>6</sub> OS		
<b>Molecular Weight:</b>	456.53		
<b>Target:</b>	Dopamine Receptor		
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 125 mg/mL (273.80 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Mass		
	1 mg	5 mg	10 mg
<b>1 mM</b>	2.1904 mL	10.9522 mL	21.9044 mL
<b>5 mM</b>	0.4381 mL	2.1904 mL	4.3809 mL
<b>10 mM</b>	0.2190 mL	1.0952 mL	2.1904 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

A-437203 is a selective D<sub>3</sub> receptor antagonist with K<sub>i</sub> of 71, 1.6, and 6220 nM for D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> receptors, respectively.

#### IC<sub>50</sub> & Target

K<sub>i</sub> :71 nM (D<sub>2</sub> receptor), 1.6 nM (D<sub>3</sub> receptor), 6220 nM (D<sub>4</sub> receptor)<sup>[1]</sup>

#### In Vitro

A-437203 is an antagonist with high affinity for D<sub>3</sub> receptors and relatively high selectivity compared to other dopamine receptor subtypes (44-fold selective for D<sub>3</sub> vs D<sub>2</sub>)<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

A-437203, a selective D<sub>3</sub> receptor antagonist, is initially tested alone in rat forced swim test (FST). Doses of A-437203 evaluated are 0.52, 1.75, 5.24, and 17.46 μmol/kg i.p. Doses are chosen based on the selectivity of A-437203 for D<sub>3</sub> vs D<sub>2</sub> dopamine receptors and reports indicating that the effects of A-437203 at doses of 17.46 μmol/kg (10 mg/kg) or lower are clearly mediated by D<sub>3</sub> but not D<sub>2</sub> receptors, since higher doses of the compound such as 174.6 μmol/kg (100 mg/kg) are necessary to bind and block D<sub>2</sub> receptor from the irreversible inactivation induced by the alkylating agent EEDG. ANOVA revealed no significant difference between the treatments for any of the behaviors analyzed (F<sub>4, 45</sub>=1.12, p=0.359 for

immobility,  $F_{4, 45}=0.188$ ,  $p=0.943$  for climbing, and  $F_{4, 45}=1.634$ ,  $p=0.182$  for swimming). Based on these results, the dose of 17.46  $\mu\text{mol/kg}$  i.p. of A-437203 is selected for further experiments<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Animal Administration <sup>[1]</sup>

#### Rats<sup>[1]</sup>

Male Sprague-Dawley rats weighing 250-350 g are used for these experiments. Haloperidol (0.27, 1.33, and 2.66  $\mu\text{mol/kg}$ =0.1, 0.5, and 1.0 mg/kg i.p.), A-437203 (LU-201640) (0.52, 1.75, 5.24, and 17.46  $\mu\text{mol/kg}$ =0.3, 1.0, 3.0, and 10.0 mg/kg i.p.), and L-745,870 (0.23, 1.15, 2.3, and 5.7  $\mu\text{mol/kg}$ =0.1, 0.5, 1.0, and 2.5 mg/kg i.p.) are tested initially alone in order to determine effective dose ranges. In those experiments, haloperidol, A-437203, and L-745,870 are administered i.p. 24, 5, and 0.5 h before the test swim. In the subsequent antagonism experiments, Haloperidol (0.27  $\mu\text{mol/kg}$ ), A-437203 (17.46  $\mu\text{mol/kg}$ ) or L-745,870 (1.15  $\mu\text{mol/kg}$ ) are injected i.p. 15 min prior to each quinpirole injection (0.4 and 1.0  $\mu\text{mol/kg}$  s.c.).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Basso AM, et al. Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. *Neuropsychopharmacology*. 2005 Jul;30(7):1257-68.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA